Previous Article | Next Article 
Journal of Clinical Microbiology, December 1998, p. 3579-3584, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antipneumococcal Activities of Levofloxacin and
Clarithromycin as Determined by Agar Dilution, Microdilution,
E-Test, and Disk Diffusion Methodologies
Catherine L.
Clark,1
Michael R.
Jacobs,2 and
Peter C.
Appelbaum1,*
Department of Pathology, Hershey Medical
Center, Hershey, Pennsylvania 17033,1 and
Department of Pathology, Case Western Reserve University,
Cleveland, Ohio 441062
Received 1 July 1998/Returned for modification 24 August
1998/Accepted 9 September 1998
 |
ABSTRACT |
The activities of levofloxacin and clarithromycin against 199 penicillin- and macrolide-susceptible and -resistant pneumococci were
tested by agar and microdilution methods in air and by disk diffusion
and E-test methods in air and CO2. For levofloxacin,
99.0% of strains were susceptible at
2.0 µg/ml with zone
diameters of
17 mm, regardless of incubation in air or
CO2. Although zone sizes were smaller and E-test MICs were
higher for clarithromycin in CO2 than those in air,
category differences were minor, and susceptibility rates for
clarithromycin were similar to those obtained by agar and microdilution
in air (range, 76.9 to 80.9% by all methods). For clarithromycin,
adjustment of breakpoints based upon distribution of results resulted
in susceptibility rates which were similar by all methods (75.8 to
76.9% susceptible, 0 to 1.5% intermediate, 22.6 to 23.1% resistant).
Minor discrepancies were obtained with levofloxacin for one strain
(0.5%) by microdilution and two strains (1.0%) by disk diffusion in
CO2. For clarithromycin, minor discrepancies were found in
three strains (1.5%) by microdilution, seven strains (3.5%) by agar
dilution, four strains (2.0%) by E-test in air, six strains (3.0%) by
disk diffusion in air, and five strains (2.5%) by disk diffusion in
CO2. Major discrepancies occurred with levofloxacin in one
strain (0.5%) by microdilution but were not found with clarithromycin.
Very major discrepancies were not seen with levofloxacin, but occurred
with clarithromycin in five strains (2.5%) by microdilution, three
strains (1.5%) by agar dilution, two strains (1.0%) by E-test in air,
eight strains (4.0%) by disk diffusion in air, and one strain (0.5%)
by disk diffusion in CO2.
 |
INTRODUCTION |
Streptococcus pneumoniae
continues to be a significant cause of morbidity and mortality in
humans; is the leading cause of bacterial pneumonia, sinusitis, and
otitis media; and is an important cause of meningitis. The past 5 years
have witnessed a dramatic worldwide increase in the incidence of
pneumococcal strains which are resistant to penicillin G and other
-lactam and non-
-lactam antimicrobials, such as macrolides,
clindamycin, tetracycline, chloramphenicol, and
trimethoprim-sulfamethoxazole (1, 2, 7, 8). The problem has
been exacerbated by the tendency of these strains to spread from
country to country and from continent to continent (11, 12).
In the United States, a recent study has shown that the penicillin MICs
for 23.6% of 1,527 clinically significant pneumococci from 30 U.S.
centers were
0.125 µg/ml, with 14.1% of isolates intermediate and
9.5% of isolates resistant (5). Penicillin-resistant pneumococci are more likely to be resistant to macrolides and other
unrelated agents, such as chloramphenicol, tetracycline, and
trimethoprim-sulfamethoxazole (5, 9). Erythromycin
resistance among pneumococci has increased in the United States from
approximately 0.2% in the late 1980s to 5 and 15% in some areas of
the country (4, 16). In the survey described above, 20% of
penicillin-intermediate pneumococcal strains and 49% of
penicillin-resistant strains were erythromycin resistant
(5). Pneumococcal strains that are resistant to erythromycin
exhibit cross-resistance to all other available macrolides and
azalides, such as azithromycin, clarithromycin, and roxithromycin
(5, 6, 18).
Currently available quinolones such as ciprofloxacin and ofloxacin are
either inactive or are marginally active against pneumococci, because
MICs are above or cluster around achievable serum drug levels and
susceptibility breakpoints (9, 15, 17, 19). Levofloxacin,
the l-isomer of ofloxacin, has been shown to have MICs for
all pneumococci, irrespective of their penicillin or macrolide MICs,
that are 1 or 2 dilutions lower than those of ciprofloxacin and
ofloxacin (15, 17, 19). The compound also possesses
favorable kill kinetics against these organisms (17, 19).
Currently, the National Committee for Clinical Laboratory Standards
(NCCLS) recommends incubation in air for microdilution testing and
CO2 for disk diffusion (13, 14). The
manufacturers of the E-test (AB Biodisk, Solna, Sweden) also recommend
incubation in CO2 for testing their product against
pneumococci, because 5 to 10% of strains do not grow without
CO2 on primary isolation. Because CO2 has
previously been shown to affect pneumococcal macrolide MICs (6,
18) and may also have an effect on quinolone results (3,
10), we tested the activities of levofloxacin (Fig.
1) and clarithromycin (Fig.
2) against 199 pneumococci by agar
dilution and microdilution in air and disk diffusion and E-test in air as well as CO2.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Histogram analysis of clarithromycin susceptibilities.
Blue bars indicate clarithromycin-susceptible strains, and red bars
indicate clarithromycin-resistant strains.
|
|
 |
MATERIALS AND METHODS |
Bacteria and antibiotics.
Of 199 pneumococcal isolates
tested in this study, 70 were recent penicillin-susceptible isolates
(MIC, <1.0 µg/ml) from the United States, 70 were penicillin
intermediate resistant (MIC, 0.1 to 1.0 µg/ml), and 59 were
penicillin resistant (MIC,
2.0 µg/ml). Because all strains had been
subcultured several times prior to use, all grew well in air. Cultures
were frozen at
70°C in double-strength litmus milk (Difco
Laboratories, Detroit, Mich.). Levofloxacin susceptibility powder was
obtained from Ortho McNeil Pharmaceutical, Raritan, N.J., and
clarithromycin was obtained from Abbott Laboratories, North Chicago, Ill.
Interpretation of results.
Breakpoints for levofloxacin and
clarithromycin susceptibility were
2.0 µg/ml (4.0 µg/ml is
intermediate) and
0.25 µg/ml (0.5 µg/ml is intermediate),
respectively. Corresponding zone diameters for the two compounds were
17 mm (14 to 16 mm is intermediate) and
21 mm (17 to 20 mm is
intermediate), respectively. Because of the different incubation
atmospheres for agar and microdilution (air) and CO2 (disk
diffusion) currently recommended by the NCCLS (13, 14), the
presence or absence of macrolide resistance was defined by disk
diffusion with erythromycin disks, because this has been shown to be
the most discriminating method (6); for levofloxacin, agar
dilution was considered the "gold standard": the distribution of
MICs of all quinolones (including levofloxacin) is unimodal (15,
17, 19).
Agar dilution MICs.
Agar dilution MICs were determined
according to standard methods with Mueller-Hinton agar supplemented
with 5% sheep blood, incorporating compounds at concentrations from
0.002 to 64 µg/ml in doubling dilutions (9). Inocula were
prepared by suspending growth from overnight cultures in sterile saline
to the turbidity of a 0.5 McFarland standard. Final inocula contained
104 organisms/spot. Plates were inoculated with a Steers
replicator with 3-mm-diameter inoculating pins and incubated overnight
at 35°C in air. The lowest concentration of antibiotic at which
organisms showed no growth was read as the MIC. Quality control strains (Staphylococcus aureus ATCC 29213, Escherichia
coli ATCC 25922, and Streptococcus pneumoniae ATCC
49619) were included in each run.
Microdilution MICs.
Microdilution MICs were determined by
the method recommended by the NCCLS (13), using
cation-adjusted Mueller-Hinton broth (Difco Laboratories) supplemented
with 5% lysed defibrinated horse blood. Suspensions with a turbidity
equivalent to that of a 0.5 McFarland standard were prepared by
suspending growth from blood agar plates in 2 ml of sterile saline.
Suspensions were further diluted 1:10 to obtain a final inoculum of
5 × 105 CFU/well. Trays were incubated overnight in
ambient air at 35°C. Standard quality control strains (as described
above) were included in each run.
E-test MICs.
Standard methodology was used to determine
E-test MICs (3, 10). Mueller-Hinton plates supplemented with
added 5% sheep blood (Cleveland Scientific, Cleveland, Ohio) were
inoculated with a 0.5 McFarland suspension scraped from plates, and
E-test strips (AB Biodisk) were placed on each plate. After overnight incubation at 35°C, the MIC was read as the intersect where the ellipse of growth inhibition intersects the strip. E-test MICs were
determined both in air and in CO2.
Disk diffusion.
Disk diffusion testing was performed by
standard NCCLS methodology (14), using Mueller-Hinton plates
supplemented with 5% added sheep blood (Cleveland Scientific)
inoculated with a 0.5 McFarland suspension. After overnight incubation
in both air and 5% CO2 at 35°C, zone diameters were
measured with calipers.
 |
RESULTS |
With erythromycin disk diffusion as the reference method
(6), 153 strains were susceptible, 2 were intermediate, and
44 were resistant to erythromycin. The results from the four
susceptibility testing methods are presented in Table
1. Table 2
presents the number of strains susceptible, intermediate, and resistant
to clarithromycin with the NCCLS breakpoints as well as adjusted breakpoints obtained by inspection of histograms of the data (Fig. 2).
As can be seen, use of NCCLS breakpoints with all methods resulted in
153 to 161 strains susceptible, 0 to 7 intermediate, and 32 to 46 resistant to clarithromycin. Analysis of histograms suggested that
breakpoints for all methods except the E-test in CO2 should
be adjusted. Use of these adjusted breakpoints resulted in improved
correlation for all methods, with 151 to 153 susceptible, 0 to 3 intermediate, and 45 to 46 resistant.
Levofloxacin MICs were unaffected by the penicillin and clarithromycin
susceptibility of strains or by test methodology;
99% of strains
were susceptible to levofloxacin at
2.0 µg/ml or
17 mm. Although
incubation of disks and E-tests in CO2 led to a slight decrease in zone sizes and increase in MICs, these did not result in
differences in category or susceptibility rates (Table 1). The
levofloxacin results are also presented graphically in Fig. 1. As can
be seen, a unimodal distribution was found by all four methods.
With the clarithromycin disk diffusion method tested by incubation in
CO2, 94.4% of penicillin-susceptible strains, 81.4% of
penicillin-intermediate strains, and 52.5% of penicillin-resistant strains were susceptible to clarithromycin. Corresponding rates when
clarithromycin disks were incubated in air were 96.1, 84.5, and 54.5%,
respectively. Although clarithromycin zone sizes were smaller and
E-test MICs were higher in CO2 than those in air, susceptibility rates were similar to those obtained by agar and microdilution in air, ranging from 76.9 to 80.9% for all methods (Table 1).
Categorical discrepancies among the four methods (all calculated with
levofloxacin agar dilution and erythromycin disk diffusion for
clarithromycin as the standard) are presented in Table
3. With levofloxacin, minor discrepancies
were obtained in one strain by microdilution and two strains by disk
diffusion in CO2, and with clarithromycin, minor
discrepancies were obtained in three strains by microdilution, seven
strains by agar dilution, four strains by E-test in air, six strains by
disk diffusion in air, and five strains by disk diffusion in
CO2. Some of the latter strains showed discrepancies in
more than one method. Major discrepancies occurred with levofloxacin in
one strain by microdilution; no major discrepancies were found with
clarithromycin. In contrast, very major discrepancies were not seen
with levofloxacin, but did occur with clarithromycin in five strains by
microdilution, three strains by agar dilution, two strains by E-test in
air, eight strains by disk diffusion in air, and one strain by disk diffusion in CO2.
 |
DISCUSSION |
As reported previously, levofloxacin MICs were similar in all
penicillin categories for pneumococci (15, 17, 19); in contrast, clarithromycin MICs were higher for penicillin-intermediate and, especially, fully resistant strains than those for
penicillin-susceptible organisms (5, 18).
The results of the current study show an excellent correlation between
the results obtained by disk diffusion, agar dilution, microdilution,
and E-test for levofloxacin, with slightly higher MICs on agar than
those of other methods. According to current NCCLS guidelines,
99%
susceptibility rates with the four methods were obtained, irrespective
of whether E-test and disk diffusion tests were incubated in air or
CO2. Because MICs of levofloxacin for pneumococci cluster 1 dilution below the breakpoint of 2.0 µg/ml (13), the
accuracy of a method recommended for use in the clinical laboratory is
important. In our hands, both E-test and disk diffusion can be
recommended for routine levofloxacin pneumococcal testing. Incubation
in CO2 did not result in differences in levofloxacin
susceptibility category or susceptibility rates. Bolmström and
Karlsson (3) have recently reported that pneumococcal MICs
of 12 quinolones (including levofloxacin) agreed within 1 dilution in
95% of cases with or without CO2, with MICs minimally changed by CO2.
Although disk testing by erythromycin is our recommended method for
screening of pneumococci for macrolide susceptibility, for
macrolide-susceptible strains, clarithromycin has been shown, both by
us and by others, to be more active than erythromycin (and also
azithromycin, dirithromycin, and roxithromycin) (6, 18, 19).
Incubation in CO2 led to higher E-test MICs and smaller
zone diameters with clarithromycin than those with incubation in air. In a previous study, Fasola and coworkers (6) have
documented that erythromycin and clindamycin MICs were 1 to 2 dilutions
higher in CO2 than in air with both the microdilution and
agar dilution MIC methodology. However, as observed by Fasola et al.
(6), raised MICs and zone sizes in CO2 did not
lead to a significant difference in susceptibility rates of pneumococci
when compared to those in air. The observed difference in MICs in and
out of CO2 may be due to improved organism growth in
CO2 or macrolide inactivation caused by
CO2-induced lowering of the pH of the medium. Visalli et
al. (18) have shown that agar dilution MICs in air for
pneumococci were lower than those in CO2 of erythromycin, azithromycin, clarithromycin, dirithromycin, and roxithromycin. The
MICs for many strains showed they were susceptible in air, but MICs
were at or near the susceptible breakpoint in CO2. The five
very major discrepancies found with clarithromycin by microdilution in
air compared to agar dilution may be due to poorer growth in broth than
on agar. This phenomenon requires confirmation with more strains and by
other workers.
It should be noted that NCCLS macrolide breakpoints for pneumococci
have been established for microdilution MICs with incubation in air.
There is thus a need for establishment by the NCCLS of macrolide
breakpoints for incubation of agar and microdilution tests under
CO2, especially for the 5 to 10% of strains which do not
grow adequately in air at primary isolation.
 |
ACKNOWLEDGMENT |
This study was supported by a grant from the R. W. Johnson
Research Institute, Raritan, N.J.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Hershey Medical Center, 500 University Dr., Hershey, PA
17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail:
pappelbaum{at}psghs.edu.
 |
REFERENCES |
| 1.
|
Appelbaum, P. C.
1992.
Antimicrobial resistance in Streptococcus pneumoniae an overview.
Clin. Infect. Dis.
15:77-83[Medline].
|
| 2.
|
Block, S.,
J. Hedrick,
P. Wright,
R. Finger,
R. Leggiadro,
M. Appleton,
S. Kahn, and R. Hutcheson.
1994.
Drug-resistant Streptococcus pneumoniae Kentucky and Tennessee, 1993.
Morbid. Mortal. Weekly Rep.
43:23-25[Medline], 31.
|
| 3.
|
Bolmstrom, A., and C. Karlsson.
1997.
The influence of CO2 incubation on MICs of quinolones tested with S. pneumoniae and H. influenzae, abstr. D-35, p. 89.
In
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 4.
|
Breiman, R. F.,
J. C. Butler,
F. C. Tenover,
J. A. Elliott, and R. R. Facklam.
1994.
Emergence of drug-resistant pneumococcal infections in the United States.
JAMA
271:1831-1835[Abstract].
|
| 5.
|
Doern, G. V.,
A. Brueggemann,
H. P. Holley, Jr., and A. M. Rauch.
1996.
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.
Antimicrob. Agents Chemother.
40:1208-1213[Abstract].
|
| 6.
|
Fasola, E. L.,
S. Bajaksouzian,
P. C. Appelbaum, and M. R. Jacobs.
1997.
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.
Antimicrob. Agents Chemother.
41:129-134[Abstract].
|
| 7.
|
Friedland, I. R., and G. S. Istre.
1992.
Management of penicillin-resistant pneumococcal infections.
Pediatr. Infect. Dis. J.
11:433-435[Medline].
|
| 8.
|
Friedland, I. R., and G. H. McCracken, Jr.
1994.
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N. Engl. J. Med.
331:377-382[Free Full Text].
|
| 9.
|
Jacobs, M. R.
1992.
Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.
Clin. Infect. Dis.
15:119-127[Medline].
|
| 10.
|
Jones, R. N.,
M. E. Erwin, and J. L. Croco.
1996.
Critical appraisal of E test for the detection of fluoroquinolone resistance.
J. Antimicrob. Chemother.
38:21-25[Abstract/Free Full Text].
|
| 11.
|
McDougal, L. K.,
R. Facklam,
M. Reeves,
S. Hunter,
J. M. Swenson,
B. C. Hill, and F. C. Tenover.
1992.
Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.
Antimicrob. Agents Chemother.
36:2176-2184[Abstract/Free Full Text].
|
| 12.
|
Munoz, R.,
J. M. Musser,
M. Crain,
D. E. Briles,
A. Marton,
A. J. Parkinson,
U. Sorensen, and A. Tomasz.
1992.
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.
Clin. Infect. Dis.
15:112-118[Medline].
|
| 13.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A4.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 14.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disk susceptibility tests. NCCLS publication no. M2-A6.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 15.
|
Pankuch, G. A.,
M. R. Jacobs, and P. C. Appelbaum.
1995.
Activity of CP 99,219 compared to DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.
J. Antimicrob. Chemother.
35:230-232[Free Full Text].
|
| 16.
|
Spika, J. S.,
R. R. Facklam,
B. D. Plikaytis,
M. J. Oxtoby, and the Pneumococcal Surveillance Working Group.
1991.
Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987.
J. Infect. Dis.
163:1273-1278[Medline].
|
| 17.
|
Visalli, M. A.,
M. R. Jacobs, and P. C. Appelbaum.
1996.
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Antimicrob. Agents Chemother.
40:362-366[Abstract].
|
| 18.
|
Visalli, M. A.,
M. R. Jacobs, and P. C. Appelbaum.
1997.
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Antimicrob. Agents Chemother.
41:1867-1870[Abstract].
|
| 19.
|
Visalli, M. A.,
M. R. Jacobs, and P. C. Appelbaum.
1997.
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Diagn. Microbiol. Infect. Dis.
28:131-137[Medline].
|
Journal of Clinical Microbiology, December 1998, p. 3579-3584, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wright, D. H., Brown, G. H., Peterson, M. L., Rotschafer, J. C.
(2000). Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother
46: 669-683
[Abstract]
[Full Text]
-
Waites, K., Johnson, C., Gray, B., Edwards, K., Crain, M., Benjamin, W. Jr.
(2000). Use of Clindamycin Disks To Detect Macrolide Resistance Mediated by ermB and mefE in Streptococcus pneumoniae Isolates from Adults and Children. J. Clin. Microbiol.
38: 1731-1734
[Abstract]
[Full Text]
-
Ednie, L. M., Jacobs, M. R., Appelbaum, P. C.
(2000). Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods. J Antimicrob Chemother
45: 525-528
[Abstract]
[Full Text]
-
Davies, T. A., Kelly, L. M., Jacobs, M. R., Appelbaum, P. C.
(2000). Antipneumococcal Activity of Telithromycin by Agar Dilution, Microdilution, E Test, and Disk Diffusion Methodologies. J. Clin. Microbiol.
38: 1444-1448
[Abstract]
[Full Text]
-
Kelly, L. M., Jacobs, M. R., Appelbaum, P. C.
(1999). Comparison of Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methods for Testing Activity of Cefditoren against Streptococcus pneumoniae. J. Clin. Microbiol.
37: 3296-3299
[Abstract]
[Full Text]